2616 KYG2588M1006

Report

Delayed Hong Kong Stock Exchange - 03/31 04:08:07 am EDT
5.040	HKD		-9.84%

05/17	CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim	AQ
05/16	CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC	CI
04/28	CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022	AQ

News

All News

Official Publications

Sector news

All news about CSTONE PHARMACEUTICALS

05/17	CStone announces final PFS analysis of a registrational study of sugemalimab in patient..	AQ
05/16	CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemali..	CI
04/28	CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and an..	AQ
04/22	CStone Announces Results From Phase 3 AGILE Data of TIBSOVO	AQ
04/21	CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of..	CI
04/13	CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Th..	AQ
04/12	CStone Pharma Presents Immunotherapy Candidate's Preclinical Data at US Oncology Confer..	MT
04/12	CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific A..	CI
03/31	CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of ..	AQ
03/30	CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Cl..	CI
03/18	CStone announced the global multi-regional registration trial of anti-PD-1 antibody nof..	AQ
03/17	CStone Pharmaceuticals Announces the Acceptance of New Drug Application for Pralsetinib..	CI
03/17	Cstone Pharmaceuticals Announces Global Multi-Regional Registration Trial of Anti-PD-1 ..	CI
03/16	CStone's partner Servier announces significant developments for TIBSOVO (ivosidenib tab..	AQ
03/14	CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanc..	AQ
03/13	China OKs CStone Pharma's Supplemental NDA for Cancer Treatment; Shares Slide 5%	MT
03/13	CStone Pharmaceuticals Announces the NMPA Approval of GAVRETO (pralsetinib) for the Tre..	CI
02/16	Taiwan Accepts CStone's New Drug Application for Lung, Thyroid Cancer Therapy	MT
02/16	CStone Pharmaceuticals Announces the Acceptance of New Drug Application for Pralsetinib..	CI
02/09	CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO (ivosidenib ..	AQ
02/08	CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibs..	CI
01/19	CStone announced two key phase 3 registrational clinical trials of sugemalimab complete..	AQ
01/19	EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically S..	CI
01/18	CStone Pharma Says Lung Cancer Treatment Improves Overall Survival of Patients in Clini..	MT
01/18	CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall surv..	PR
01/18	CStone Pharmaceuticals Announces Gemstone-302 Study of Sugemalimab Met the Endpoint of ..	CI
01/17	CStone Pharma Completes Patient Enrollment for Two Key Studies of Cancer Drug; Shares J..	MT
01/17	CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Suge..	CI
01/16	CStone Pharma's Lung Cancer Treatment Featured in Medical Journal	MT
01/14	CStone Pharmaceuticals Announces the Clinical Data from Registrational Study of Sugemal..	CI
01/14	Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalim..	CI
01/12	CStone Pharma's Investigational Antibody Boosts Objective Response Rate of Lymphoma Pat..	MT
01/12	CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response ..	CI
01/04	CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in..	AQ
01/04	CStone Pharma Gets Nod to Start China Study of Therapy for ROS1-Positive Lung Cancer	MT
01/04	CStone Announces IND Approval for the Pivotal Study in China of Lorlatinib for the Trea..	CI
01/03	CStone Pharma Gets FDA Nod to Begin US Clinical Trial of Therapy Targeting ROR1 Cancer ..	MT
01/03	CStone Pharmaceuticals Announces the IND Approval of CS5001, a Potential Global Best-In..	CI
2021	CStone Pharmaceuticals announced new drug approval for precision therapy AYVAKIT (avapr..	AQ
2021	CStone Pharmaceuticals Unaware of Unusual Share Price and Trading Volume Movements	MT
2021	Hong Kong Approves CStone Pharma's Precision Therapy for Gastrointestinal Stromal Tumor	MT
2021	CStone Announces New Drug Approval of Precision Therapy AYVAKIT® (Avapritinib) in Hong ..	CI
2021	Ligand's partner cstone pharmaceuticals receives approval in china for sugemalimab (cej..	AQ
2021	Ligand Pharmaceuticals' Partner Gets Approval for Lung Cancer Drug in China	MT
2021	CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the Fi..	CI
2021	China Approves CStone Pharma Drug for Stage IV Lung Cancer Treatment	MT
2021	Cstone announced new drug approval of cejemly® (sugemalimab) in china to potentially re..	AQ
2021	CStone Pharmaceuticals Announces New Drug Approval of Cejemly (Sugemalimab) in China to..	CI
2021	Transcenta Hires Former CStone Pharma Exec as CFO	MT
2021	CStone Pharmaceuticals - Phase 3 Data Show That TIBSOVO in Combination with Azacitidine..	AQ
2021	CStone Pharmaceuticals' Leukemia Drug, Chemotherapy Improves Patient Survival in Phase ..	MT
2021	Cstone Pharmaceuticals Announces Executive Changes	CI
2021	CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater C..	MT
2021	CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnersh..	AQ
2021	Cstone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Announce Strategic Partnersh..	CI
2021	CStone Pharma Strikes Antibody Therapy Collaboration Deal with Singapore's DotBio	MT
2021	CStone Pharmaceuticals and DotBio Pte. Ltd enter into a collaboration agreement	CI
2021	CStone's partner, Servier, will present the first Phase 3 results from the global AGILE..	AQ
2021	CStone Pharmaceuticals Received China NMPA IND Acceptance for lorlatinib in Chinese Pat..	CI
2021	CSTONE PHARMACEUTICALS : Chinese Regulators OK CStone's Investigational New Drug Applicati..	MT
2021	CSTONE PHARMACEUTICALS : presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-..	AQ
2021	CSTONE PHARMACEUTICALS : Achieves Potential Antitumor Activity From Preclinical Antibody T..	MT
2021	CStone Presents Arrow Study Data for GAVRETO? (Pralsetinib) in Chinese Patients with Re..	CI
2021	CSTONE PHARMACEUTICALS : announced that the research data of CS5001 (ROR1 ADC) has been se..	AQ
2021	CSTONE PHARMACEUTICALS : Pharma Presents Cancer Drug's Bridging Study Data at Oncology Con..	MT
2021	CSTONE PHARMACEUTICALS : presents preliminary results from a phase Ib study of the anti-CT..	AQ
2021	CStone Pharmaceuticals Presents Clinical Data from the China Registrational Bridging St..	CI
2021	CSTONE PHARMACEUTICALS' : Investigational Cancer Treatment Shows Potential in Phase 1b Tri..	MT
2021	Cstone Presents Preliminary Results from Phase Ib Study of the Anti-Ctla-4 Monoclonal A..	CI
2021	EQRx and its Partner CStone Pharmaceuticals Announce Presentation of Phase 3 Data Demon..	CI
2021	CStone Pharmaceuticals Will Present Registrational Clinical Study Data of Sugemalimab i..	CI
2021	CSTONE PHARMACEUTICALS : to Present Phase 3 Trial Data of Non-Small Cell Lung Cancer Treat..	MT
2021	CSTONE PHARMACEUTICALS : received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-..	AQ
2021	CSTONE PHARMACEUTICALS : Wins Chinese Regulators' OK to Start Clinical Trial of Advanced S..	MT
2021	CStone Pharmaceuticals Receives China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4..	CI

1 2 3 4 Next

Upcoming event on CSTONE PHARMACEUTICALS

08/25/22

Interim 2022 Earnings Release (Projected)

Company calendar

Upcoming sector events

07/27/22	VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
07/27/22	GILEAD SCIENCES, INC. : Interim 2022 Earnings Release (Projected)
08/04/22	REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22	BIONTECH SE : Interim 2022 Earnings Release

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Bio Therapeutic Drugs